ChemicalBook
Chinese english Germany Korea

シプロフロキサシン

シプロフロキサシン 化学構造式
85721-33-1
CAS番号.
85721-33-1
化学名:
シプロフロキサシン
别名:
1-シクロプロピル-1,4-ジヒドロ-6-フルオロ-4-オキソ-7-(1-ピペラジニル)-3-キノリンカルボン酸;1,4-ジヒドロ-1-シクロプロピル-6-フルオロ-4-オキソ-7-(1-ピペラジニル)キノリン-3-カルボン酸;1-シクロプロピル-6-フルオロ-1,4-ジヒドロ-4-オキソ-7-(1-ピペラジニル)キノリン-3-カルボン酸;シフロキノン;1-シクロプロピル-6-フルオロ-4-オキソ-7-(1-ピペラジニル)-1,4-ジヒドロキノリン-3-カルボン酸;1-シクロプロピル-6-フルオロ-4-オキソ-7-(1-ピペラジニル)-1,4-ジヒドロ-3-キノリンカルボン酸;フロキシール;シフロサシン;シプロキサシン;ペイトン;6-フルオロ-1-シクロプロピル-1,4-ジヒドロ-4-オキソ-7-ピペラジノキノリン-3-カルボン酸;1-シクロプロピル-1,4-ジヒドロ-6-フルオロ-4-オキソ-7-(1-ピペラジニル)キノリン-3-カルボン酸;1-シクロプロピル-1,4-ジヒドロ-4-オキソ-6-フルオロ-7-ピペラジノキノリン-3-カルボン酸;プリモール;1-シクロプロピル-1,4-ジヒドロ-6-フルオロ-7-(1-ピペラジニル)-4-オキソキノリン-3-カルボン酸;ベンジング;1-シクロプロピル-6-フルオロ-7-(1-ピペラジニル)-1,4-ジヒドロ-4-オキソキノリン-3-カルボン酸;1-シクロプロピル-6-フルオロ-1,4-ジヒドロ-4-オキソ-7-(1-ピペラジニル)-3-キノリンカルボン酸;1-シクロプロピル-6-フルオロ-7-ピペラジノ-4-オキソ-1,4-ジヒドロキノリン-3-カルボン酸;1-シクロプロピル-6-フルオロ-1,4-ジヒドロ-7-ピペラジノ-4-オキソキノリン-3-カルボン酸
英語化学名:
Ciprofloxacin
英語别名:
CPFX;Cipro;Baycip;ciloxan;ciproiv;Ciprine;Cipmbay;ciprobid;CIPROBAY;euciprin
CBNumber:
CB7217221
化学式:
C17H18FN3O3
分子量:
331.34
MOL File:
85721-33-1.mol

シプロフロキサシン 物理性質

融点 :
255-257°C
貯蔵温度 :
Store at 0-5°C
溶解性:
Soluble in 0.1N HCl at 25mg/ml. Poorly soluble in DMSO
酸解離定数(Pka):
pKa 4.04 (Uncertain)
外見 :
powder
Merck :
14,2314
BRN :
3568352
CAS データベース:
85721-33-1(CAS DataBase Reference)
EPAの化学物質情報:
3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4- dihydro-4-oxo-7-(1-piperazinyl)- (85721-33-1)

安全性情報

主な危険性  Xi
Rフレーズ  36/37/38
Sフレーズ  26-36-24/25
RIDADR  UN 3077 9 / PGIII
WGK Germany  2
RTECS 番号 VB1993800
HSコード  29339900
有毒物質データの 85721-33-1(Hazardous Substances Data)

シプロフロキサシン 価格 もっと(24)

メーカー 製品番号 製品説明 CAS番号 包装 価格 更新時間 購入
富士フイルム和光純薬株式会社(wako) W01COBQA-8228 シプロフロキサシン
Ciprofloxacin
85721-33-1 1g ¥3600 2018-12-26 購入
富士フイルム和光純薬株式会社(wako) W01COBQA-8228 シプロフロキサシン
Ciprofloxacin
85721-33-1 5g ¥7200 2018-12-26 購入
東京化成工業 C2510 シプロフロキサシン >98.0%(HPLC)(T)
Ciprofloxacin >98.0%(HPLC)(T)
85721-33-1 25g ¥10800 2018-12-04 購入
東京化成工業 C2510 シプロフロキサシン >98.0%(HPLC)(T)
Ciprofloxacin >98.0%(HPLC)(T)
85721-33-1 5g ¥3400 2018-12-04 購入
Sigma-Aldrich Japan 1134313 シプロフロキサシン United States Pharmacopeia (USP) Reference Standard
Ciprofloxacin United States Pharmacopeia (USP) Reference Standard
85721-33-1 200mg ¥57200 2018-12-25 購入

シプロフロキサシン 化学特性,用途語,生産方法

用途

シプロフロキサシンは広域抗生物質であり、グラム陰性、グラム陽性のいずれのバクテリアにも活性である。デオキシリボ核酸二本鎖の切断?再結合を行う酵素であるDNAジャイレース(DNAトポイソメラーゼの一種)に結合し、DNAの複製を阻害することで抗菌作用を示す。DNAの複製が阻害されることで、バクテリアは細胞分裂ができなくなる。

効能

抗菌薬, 核酸合成阻害薬

商品名

シプロキサン (バイエル薬品)

説明

Ciprofloxacin is a quinolone antibacterial related to recently marketed norfloxacin (10), ofloxacin (2), pefloxacin (2) and enoxacin. It has a broad spectrum of activity against gram-positive and gram-negative bacteria, and is useful in the treatment of urinary and upper respiratory tract infections.

化学的特性

White Powder

Originator

Bayer (W. Germany)

使用

Fluorinated quinolone antibacterial

定義

ChEBI: A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.

brand name

Cipro (Bayer);CIPROBAY.

抗菌性

It exhibits potent activity against most Enterobacteriaceae, as well as against Acinetobacter spp. (MIC 0.25–1 mg/L), fastidious Gram-negative bacilli such as Mor. catarrhalis (MIC 0.06–0.25 mg/L) and Campylobacter jejuni(MIC 0.12 mg/L). In common with other quinolones, it is active against Bacillus anthracis. Ciprofloxacin is the most active quinolone against Ps. aeruginosa and exhibits good activity in vitro against other non-fermenting Gram-negative bacilli. In-vitro activity against Staph. aureus coagulase-negative staphylococci, Str. pyogenes, Str. pneumoniae and Enterococcus spp. (MIC c. 0.5–2 mg/L) is moderate. Most methicillin-resistant strains of staphylococci are resistant. It has poor activity against anaerobes, but is active against M. tuberculosis, Mycoplasma spp. and intracellular pathogens such as Chlamydia, Chlamydophila and Legionella.

応用例(製薬)

A 6-fluoro, 7-piperazinyl quinolone formulated as the hydrochloride for oral administration and as the lactate for intravenous use.

薬物動態学

Oral absorption: 50–80%
Cmax 500 mg oral: 1.5–2 mg/L after 1–2 h
200 mg intravenous (15-min infusion): 3.5 mg/L end infusion
Plasma half-life: 3–4 h
Volume ofdistribution: 3–4 L/kg
Plasma protein binding: 20–40%
Absorption
After escalating oral doses, mean peak plasma levels increase proportionately with dose. However, accumulation occurs after repeated doses of 500 mg orally or 200 mg intravenously every 12 h: the apparent elimination half-life has been reported to rise to about 6 h after a regimen of 250 mg every 12 h for 6 days. Absorption is delayed, but seems unaffected by food and, in common with other quinolones, is reduced by certain antacids. Co-administration of sucralfate reduces the peak plasma concentrations to undetectable levels in many subjects (mean value from 2 to 0.2 mg/L) and the AUC is reduced to 12% of the value obtained when ciprofloxacin is administered alone. Ferrous sulfate and multivitamin preparations containing zinc significantly reduce absorption, which is also impaired in patients receiving cytotoxic chemotherapy for hematological malignancies. Calculated total bioavailability is 60–70%.
Distribution
It is widely distributed in body fluids, concentrations in most tissues and in phagocytic cells approximating those in plasma. Concentrations in the CSF, even in the presence of meningitis, are about half the simultaneous plasma levels.
Metabolism and excretion
It is partly metabolized to four metabolites, all but one of which (desethylciprofloxacin) display antibacterial activity. About 95% of a dose can be recovered from feces and urine. Around 40% of an oral and 75% of an intravenous dose appear in the urine over 24 h. Elimination is by both glomerular filtration and tubular secretion (60–70%) and is reduced by concurrently administered probenecid and by renal insufficiency. It is poorly removed by hemodialysis. Part of the administered drug is eliminated in the bile. An enterohepatic cycle results in prolongation of the half-life. The four metabolites are eliminated in the urine and feces at low concentration in comparison to the parent compound.

副作用

Untoward reactions are uncommon, those encountered being typical of the group. Reactions severe enough to require withdrawal of treatment have occurred in <2% of patients. The most common reactions, gastrointestinal tract disturbances, have been seen in 5% of patients and rashes in about 1%. CNS disturbances typical of quinolones have been reported in 1–2% of patients. Tendinitis and tendon rupture (especially of the Achilles tendon) may occur in a small number of patients and ciprofloxacin should be avoided in patients at risk for these conditions. Potentiation of the action of theophylline and other drugs metabolized by microsomal enzymes may occur. Crystalluria and transient arthralgia have been reported.
In volunteers, dosages of up to 750 mg produced no change in the numbers of fecal streptococci and anaerobes, but did produce a 2.5 × log10 decline in the numbers of enterobacteria, which lasted 1 week. There was no change in the susceptibility of the affected organisms and no overgrowth by resistant strains. As with other quinolones, ciprofloxacin is not recommended for use in children or in pregnant or lactating women.
The drug should be avoided in suspected or confirmed infections caused by Str. pneumoniae. It is inferior to conventional agents and some other fluoroquinolones in the treatment of genital tract infections caused by C. trachomatis.
Ciprofloxacin has also been shown to be effective in the treatment of patients with malignant otitis externa, catscratch disease, prevention of infection in patients undergoing biliary tract surgery, and treatment of biliary tract infections. A topical preparation for use in the treatment of ocular infections is available, but is neither more effective nor safer than established topical agents; it may be indicated for superficial eye infections caused by pathogens resistant to conventional drugs or in patients unable to tolerate standard therapeutic agents.

シプロフロキサシン 上流と下流の製品情報

原材料

準備製品


シプロフロキサシン 生産企業

Global( 280)Suppliers
名前 電話番号 ファックス番号 電子メール 国籍 製品カタログ 優位度
Hebei Guanlang Biotechnology Co., Ltd.
+86-0311-66562153 whatsapp +8615203118427
+86-0311-66562153 sales@crovellbio.com CHINA 407 50
Capot Chemical Co.,Ltd.
+86 (0)571-855 867 18
+86 (0)571-858 647 95 sales@capotchem.com China 19918 60
Shenzhen Sendi Biotechnology Co.Ltd.
0755-23311925 18102838259
0755-23311925 Abel@chembj.com CHINA 3203 55
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 20680 55
Mainchem Co., Ltd.
+86-0592-6210733
+86-0592-6210733 sales@mainchem.com CHINA 32457 55
PI & PI BIOTECH INC.
020-81716320
020-81716319 Sales@pipitech.com CHINA 2543 55
Nanjing ChemLin Chemical Industry Co., Ltd.
025-83697070;product@chemlin.com.cn
product@chemlin.com.cn CHINA 3015 60
Hefei TNJ Chemical Industry Co.,Ltd.
86-0551-65418684 18949823763
86-0551-65418684 info@tnjchem.com China 1730 55
Xiamen AmoyChem Co., Ltd
+86 (0)592-605 1114
sales@amoychem.com CHINA 6374 58
Hubei Jusheng Technology Co.,Ltd.
86-188-71490254
peter@hubeijusheng.com CHINA 20095 58

85721-33-1(シプロフロキサシン)キーワード:


  • 85721-33-1
  • 3-quinolinecarboxylicacid,1,4-dihydro-1-cyclopropyl-6-fluoro-4-oxo-7-(1-piper
  • ciloxan
  • ciprobid
  • ciproiv
  • euciprin
  • CIPROBAY
  • CIPROFLOXACIN
  • CIPROFLOXACIN BASE
  • BAYQ 3939
  • 1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-4-OXO-7-(1-PIPERAZINYL)-3-QUINOLINECARBOXYLIC ACID
  • 1-CYCLOPROPYL-6-FLUORO-4-OXO-7-PIPERAZIN-1-YL-1,4-DIHYDRO-QUINOLINE-3-CARBOXYLIC ACID
  • AKOS BBS-00004646
  • AKOS 92631
  • 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-
  • 1-cyclopropyl-6-fluoro-7-(1-piperazinyl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid
  • 1-cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydro-3-quinolinecarbox
  • CIPROFLOXACIN USP 24
  • Ciprofloxacin (Cipro)
  • Ciflafin
  • Ciprine
  • Ciprobay 100
  • Ciprofloxacillin
  • Enrofloxacin EP Impurity B
  • 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid HCl
  • 1-cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid hydrochloride
  • 3-Quinolinecarboxylic a
  • Clprofloxacin
  • Ciprofloxaicin USP
  • Ciprofloxacin Solution, 1000ppm
  • Enrofloxacin Impurity 2(Enrofloxacin EP Impurity B)
  • 1-シクロプロピル-1,4-ジヒドロ-6-フルオロ-4-オキソ-7-(1-ピペラジニル)-3-キノリンカルボン酸
  • 1,4-ジヒドロ-1-シクロプロピル-6-フルオロ-4-オキソ-7-(1-ピペラジニル)キノリン-3-カルボン酸
  • 1-シクロプロピル-6-フルオロ-1,4-ジヒドロ-4-オキソ-7-(1-ピペラジニル)キノリン-3-カルボン酸
  • シフロキノン
  • 1-シクロプロピル-6-フルオロ-4-オキソ-7-(1-ピペラジニル)-1,4-ジヒドロキノリン-3-カルボン酸
  • 1-シクロプロピル-6-フルオロ-4-オキソ-7-(1-ピペラジニル)-1,4-ジヒドロ-3-キノリンカルボン酸
  • フロキシール
  • シフロサシン
  • シプロキサシン
  • ペイトン
  • 6-フルオロ-1-シクロプロピル-1,4-ジヒドロ-4-オキソ-7-ピペラジノキノリン-3-カルボン酸
  • 1-シクロプロピル-1,4-ジヒドロ-6-フルオロ-4-オキソ-7-(1-ピペラジニル)キノリン-3-カルボン酸
  • 1-シクロプロピル-1,4-ジヒドロ-4-オキソ-6-フルオロ-7-ピペラジノキノリン-3-カルボン酸
  • プリモール
  • 1-シクロプロピル-1,4-ジヒドロ-6-フルオロ-7-(1-ピペラジニル)-4-オキソキノリン-3-カルボン酸
  • ベンジング
  • 1-シクロプロピル-6-フルオロ-7-(1-ピペラジニル)-1,4-ジヒドロ-4-オキソキノリン-3-カルボン酸
  • 1-シクロプロピル-6-フルオロ-1,4-ジヒドロ-4-オキソ-7-(1-ピペラジニル)-3-キノリンカルボン酸
  • 1-シクロプロピル-6-フルオロ-7-ピペラジノ-4-オキソ-1,4-ジヒドロキノリン-3-カルボン酸
  • 1-シクロプロピル-6-フルオロ-1,4-ジヒドロ-7-ピペラジノ-4-オキソキノリン-3-カルボン酸
  • シバスタン
  • 1-シクロプロピル-4-オキソ-6-フルオロ-7-ピペラジノ-1,4-ジヒドロキノリン-3-カルボン酸
  • 1-シクロプロピル-4-オキソ-6-フルオロ-7-(1-ピペラジニル)-1,4-ジヒドロ-3-キノリンカルボン酸
  • シプキサノン
  • 1-シクロプロピル-6-フルオロ-1,4-ジヒドロ-7-(1-ピペラジニル)-4-オキソキノリン-3-カルボン酸
  • ジスプロチン
  • 1-シクロプロピル-4(1H)-オキソ-6-フルオロ-7-(ピペラジノ)キノリン-3-カルボン酸
  • シプロキサシン[商品名]
  • シプロフロキサシン
  • シプロフロキサシン (JP17)
  • キノロン系抗細菌薬
Copyright 2017 © ChemicalBook. All rights reserved